The trial, sponsored by Universitat Politècnica de València, evaluates a dual-hormone artificial pancreas system against a single-hormone configuration in adults with Type 1 Diabetes (T1D). The dual-hormone approach aims to reduce hypoglycemic events and improve time in target glucose range, addressing a significant unmet need in diabetes management. The market for diabetes management technologies is expanding, with increasing adoption of automated insulin delivery systems. Successful outcomes could position the dual-hormone system as a competitive alternative to existing single-hormone systems, potentially enhancing patient adherence and outcomes. Companies in the diabetes technology space should monitor this trial closely for implications on product development and market positioning.